North American Business Development Opportunities

Business Opportunities
North America
Benefits of Partnering with Apotex

Apotex is a leader in the North American generic pharmaceutical market with #1 ranking in Canada in terms of prescriptions filled, sales volume and value, and a Top 10 position in the U.S.A.

We are a vertically integrated company. Our preference is to develop, manufacture and market our own products — from API to finished dosage form to marketing and distribution.

Apotex does however have an interest in complimenting its own product portfolio/pipeline with products from third parties where they can offer:

  • Early to market opportunities
  • Dosage Forms Apotex does not manufacture

Examples of our successful collaboration with third parties:

  • Partnership with Orchid Chemicals & Pharmaceuticals Ltd. for cephalosporin injectables for the U.S.A. and Canadian markets
  • First to launch Cefepime injection; collaboration with Orchid Chemicals & Pharmaceuticals Ltd.
  • First to launch a generic oral contraceptive product in Canada (Portia®); collaboration with Barr Pharmaceuticals, Inc.
Early to market opportunities
  • first-to-file
  • non-infringing API and/or formulations

Apotex has substantial experience in identifying, developing, registering and defending litigation in early to market opportunities, including Para IV opportunities.

Dosage Forms Apotex does not manufacture:


  • Dry Powder Inhalers
  • Metered Dose Inhalers


  • Carbapenems
  • Depots
  • Hormones
  • Liposomal
  • Lyophilized
  • Penicillins
  • Semi-Synthetic Penicillins
  • Pre-filled Syringes


  • Ointments


  • Orodispersable
  • Hormones
  • Buccal/transmucosals

Schedule II controlled drugs (USA only)



  • Creams
  • Gels
  • Ointments
  • Transdermal patches

For Dosage Forms where there is an opportunity for Apotex to contribute to Formulation, Analytical Development or Clinical Development, Apotex is interested in Co-Development.